Prosecution Insights
Last updated: October 25, 2026

Nematerra Bvba

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Nematerra Bvba has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, resulting in a focused examination path. Counsel can concentrate on the specific biotechnology or pharmaceutical disclosure, the assigned art unit’s technical framework, and the precise limitations requiring response.

MOREAU, NASHARA LOUISE is the busiest examiner, with 1 pending matter. The examiner-specific record is therefore the central source for prosecution planning. A targeted response supported by clear claim-to-disclosure mapping is more appropriate than a generalized portfolio strategy, particularly where biological or pharmaceutical distinctions depend on detailed technical support.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MOREAU, NASHARA LOUISE 1 66.7% -80.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18845299 NEMATICIDAL COMPOSITION FOR CONTROL OF PLANT PARASITIC NEMATODES MOREAU, NASHARA LOUISE —

Top Art Units

Art UnitApps
1655 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18845299 NEMATICIDAL COMPOSITION FOR CONTROL OF PLANT PARASITIC NEMATODES MOREAU, NASHARA LOUISE 1655 §102§103§112 Non-Final OA — Pending Sep 09, 2024

Managing Nematerra Bvba's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Nematerra Bvba have?

Nematerra Bvba has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Nematerra Bvba applications?

Nashara Louise Moreau has the most, with 1 of Nematerra Bvba's pending office actions.

What technology area are Nematerra Bvba's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month